NCT04584658

Brief Summary

This study examines the presence, severity and natural history of dysphagia and dysphonia in the post-extubation and severely unwell COVID-19 patient.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
50

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Sep 2020

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 15, 2020

Completed
25 days until next milestone

First Submitted

Initial submission to the registry

October 10, 2020

Completed
4 days until next milestone

First Posted

Study publicly available on registry

October 14, 2020

Completed
2.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 30, 2022

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

January 30, 2023

Completed
Last Updated

June 29, 2025

Status Verified

June 1, 2025

Enrollment Period

2.2 years

First QC Date

October 10, 2020

Last Update Submit

June 26, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Primary endpoint is severity of dysphonia and dysphagia at the time of initial assessment t = day 0 (for ITU patients: Day 0 = 24 hours after extubation or decannulation).

    Based on therapy outcome measures from FEES, VoiS

    t = day 0 (for ITU patients: Day 0 = 24 hours after extubation or decannulation).

Secondary Outcomes (7)

  • The severity of dysphonia and/or dysphagia over an initial 12 month period (at t = 14 days, 1 month, 3 months, 6 months, 9 months, 12 months)

    t = 14 days, 1 month, 3 months, 6 months, 9 months, 12 months

  • The severity of dysphonia and/or dysphagia at t = day 5, day 10, day 14, day 21 - For in-patients only.

    t = day 5, day 10, day 14, day 21 - For in-patients only.

  • Relationship between severity of dysphonia and/or dysphagia with grade of ARDS

    t = day 0 and 9 months

  • Relationship between severity of dysphonia and/or dysphagia with length of intubation

    t = day 0 and 9 months

  • Relationship between severity of dysphonia and/or dysphagia with duration of mechanical ventilation

    t = day 0 and 9 months

  • +2 more secondary outcomes

Interventions

This is the use of endoscopy during feeding trials. The patient is fed different consistencies of food and drink while an endoscope is in place (usually passed through the nasal passage and down into the throat). The endoscope provides a bird's eye view to the transit of food through the upper aero-digestive tract. This provides information from the point of food bolus formation in the mouth to the movement of the base of the tongue; the movement of pharyngeal muscles; the deflection of the epiglottis to protect the airway including the closure of the vocal cords and the passage of food into the oesophagus. Any abnormality in these steps are noted during FEES. Liquids, thickened fluids, semi-solids and solids are some of the food textures that are tested.

VideofluoroscopyDIAGNOSTIC_TEST

A radio opaque dye is used to label the test food and drink items offered to the patient. Following this, x-ray technology is used to create a video of the outline of the patient and the structures responsible for chewing and swallowing as they injest the test materials. The study is carried out in real time in the radiology department in conjunction with a radiographer and an SLT.

This is a 25-item questionnaire assessing three domains: physical (9 items), functional (9 items), and emotional aspects (7 items) of the Quality of Life (QOL) in patients suffering with dysphagia. For each statement the patient checks if it applies to him/her all the time, some of the time or never. The suggested scores are 0, 2 and 4, respectively. Using this scoring system amounts to a DHI score range of 0 - 100. The higher the score, the worse the dysphagia related QOL. The patient is also asked to provide a rating of their own impression of the severity of the dysphagia experienced on a scale from 1 (normal) to 7 (severe problem).

This is a 30-item validated quality of life tool that is also a self-reporting tool. It appraises the impact of the patient's abnormal voice from an emotional perspective, related physical symptoms and stratifies the impairment itself in context of day to day activities. VoiSS is currently the most psychometrically robust voice outcome measure. Each item is scored 0 - 4 on the frequency responses: never, occasionally, some of the time, most of the time, always. The total score of 120 measures general voice pathology which is made up of Impairment = maximum score of 60; Emotional = maximum score of 32; Physical = maximum score of 28.

Eligibility Criteria

Age18 Years - 85 Years
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients identified with dysphagia and dysphonia secondary to COVID19 infection. Specifically severely unwell patients and post-extubation patients.

You may qualify if:

  • Patients who have been diagnosed with a positive SARS CoV-2 test.
  • Patients who have been diagnosed with dysphonia and/or dysphagia following COVID 19 treatment.
  • Patients who require investigation and management for dysphonia and/or dysphagia following COVID 19 treatment.
  • Adult patients aged 18 years - 85 years.
  • Patients that meet threshold for referral to the joint MDT clinic following screening

You may not qualify if:

  • Patients who cannot undertake the assessment for dysphonia and/or dysphagia.
  • Patients who are being managed with palliative intent.
  • Patients with pre-existing dysphonia and/or dysphagia not previously responding to therapy (pre-existing prior to COVID-19 diagnosis).

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Cambridge University Hospitals NHS Foundation Trust

Cambridge, CB2 0QQ, United Kingdom

Location

MeSH Terms

Conditions

Deglutition DisordersDysphoniaVoice DisordersCOVID-19Severe Acute Respiratory Syndrome

Condition Hierarchy (Ancestors)

Esophageal DiseasesGastrointestinal DiseasesDigestive System DiseasesPharyngeal DiseasesOtorhinolaryngologic DiseasesLaryngeal DiseasesRespiratory Tract DiseasesNeurologic ManifestationsNervous System DiseasesSigns and SymptomsPathological Conditions, Signs and SymptomsPneumonia, ViralPneumoniaRespiratory Tract InfectionsInfectionsVirus DiseasesCoronavirus InfectionsCoronaviridae InfectionsNidovirales InfectionsRNA Virus InfectionsLung Diseases

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Consultant Otolaryngology, Head & Neck Surgeon.

Study Record Dates

First Submitted

October 10, 2020

First Posted

October 14, 2020

Study Start

September 15, 2020

Primary Completion

November 30, 2022

Study Completion

January 30, 2023

Last Updated

June 29, 2025

Record last verified: 2025-06

Data Sharing

IPD Sharing
Will not share

Locations